United Therapeutics Corp. SEC Filings

United Therapeutics (UTHR) insider sale notice: An officer/director filed a Form 144 proposing the sale of 4,000 common shares through TD Securities (USA) LLC on 10/06/2025

The filing shows an aggregate market value of $1,798,765.20 for the 4,000 shares and reports the original acquisition on 03/15/2016 via executive deferred compensation consisting of 294,000 shares from Martine Rothblatt. The notice also lists multiple recent open-market sales by the same person between 09/09/2025 and 10/03/2025, with per-day sale quantities of 4,000 shares (one 8,000-share sale on 09/09/2025) and gross proceeds shown for each date. The filer certifies no undisclosed material information and identifies broker details and share counts but does not state total outstanding shares beyond the single row count of 45,230,000.

United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 90,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on 10/06/2025 on NASDAQ. The shares were acquired and paid for on 10/06/2025 through an exercise of stock options and funded in cash. The filing lists the aggregate market value of the shares as $40,776,300.00 and total shares outstanding as 45,226,262.

The notice also discloses multiple Rule 10b5-1 sales attributed to Michael Benkowitz during September 2025 totaling several transactions (examples: 7,875 and 14,625 share blocks) with gross proceeds reported per trade. The filer affirms no undisclosed material nonpublic information and includes the standard signature/attestation language required by the form.

United Therapeutics (UTHR) insider Martine Rothblatt filed a Form 144 to sell 4,000 common shares through TD Securities (USA) LLC on or about 10/03/2025, with an aggregate market value of $1,784,847.20. The shares are listed on NASDAQ. The filing also lists prior insider sales over the past three months, including 8,000 shares on 09/09/2025 for $3,188,374.33 and 4,000 shares on 10/02/2025 for $1,739,525.20. The table notes 45,230,000 shares outstanding.

United Therapeutics (UTHR) submitted a Form 144 reporting a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,739,525.20. The filing states 45,230,000 shares outstanding and lists the approximate sale date as 10/02/2025. The shares being offered were acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, with 294,000 shares originally received via exercised vested options and payment in common shares. The notice also discloses prior sales by the same person totaling 72,000 shares between 09/09/2025 and 10/01/2025, with daily sales recorded through mid-September to early October. The filer attests no undisclosed material information and the transaction is being executed by a broker on NASDAQ.

United Therapeutics (UTHR) reporting person Martine A. Rothblatt executed option exercises and share sales under a pre-arranged 10b5-1 trading plan entered May 2, 2025. On 10/01/2025 and 10/02/2025 she exercised a total of 8,000 stock options at an exercise price of $120.26, resulting in acquisition of 8,000 common shares. Concurrently, the filing discloses sales of a total of 8,000 common shares executed in multiple trades with weighted-average sale prices reported between $423.305 and $437.70. The 10b5-1 plan will continue until the earlier of exhaustion of a tranche of 294,000 options expiring 03/15/2026 or 12/31/2025. The report also discloses significant indirect holdings via spouse and family trusts, including trusts holding 324,518, 258,117, 45,596, and 15,962 shares.

UNITED THERAPEUTICS (UTHR) Form 144 summary: This notice reports proposed sale of 11,000 common shares to be executed through Morgan Stanley Smith Barney on 10/02/2025 on NASDAQ, with an aggregate market value listed as $4,802,572.50. The shares were acquired the same day by stock option exercise and paid in cash. The filer discloses six prior common-stock sales by the same person in the past three months, each for 11,000 shares, totaling 66,000 shares and gross proceeds of approximately $22,050,034.60. The issuer’s outstanding shares are reported as 45,226,262, making each 11,000-share block a small fraction of outstanding stock. The filer certifies no undisclosed material adverse information and signs the notice under penalties for false statements.

United Therapeutics director and Chairperson & CEO Martine A. Rothblatt reported multiple option exercises and subsequent open-market sales under a pre-arranged 10b5-1 plan entered May 2, 2025. On 09/29/2025 and 09/30/2025 she exercised two tranches of stock options at an exercise price of $120.26 each for 4,000 options per date, receiving 4,000 shares each time. Concurrently, she sold multiple blocks of common stock on 09/29/2025 and 09/30/2025 at weighted-average prices ranging from about $416.38 to $423.78, including a 4,000-share sale at $422.8394. Reported directly held and trust-held shares total hundreds of thousands of shares across listed trusts and a spouse-held position.

United Therapeutics (UTHR) Form 144 summary: This notice reports a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,891,277.50, listing an approximate sale date of 09/30/2025 on NASDAQ. The securities were originally acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, totaling 294,000 shares acquired at that time. The filing also discloses prior sales by Martine Rothblatt in September 2025 totaling 64,000 shares sold across multiple dates, with daily gross proceeds shown per trade. Outstanding shares are listed as 45,230,000, providing context for the reported transactions.

UNITED THERAPEUTICS (UTHR) Form 144: This notice reports a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,702,446.76 and shows 60,000 shares sold by Martine Rothblatt across multiple dates in September 2025. The filing records that 294,000 shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement and that the acquisition involved exercised vested options paid via common shares. The issuer has approximately 45,230,000 shares outstanding. The filer certifies no undisclosed material adverse information.